NCT03944915已完成2 期
A Phase II Trial of Carboplatin, Paclitaxel, and Nivolumab Induction Therapy Followed by Response-stratified Locoregional Therapy for Patients With Locally Advanced, HPV-negative Head and Neck Cancer. The DEPEND Trial.
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 35
- 试验地点
- 1
- 主要终点
- Deep Response Rate (DRR)
研究概览
简要总结
This study is looking to see if nivolumab, an immunotherapy drug, given with carboplatin and paclitaxel (2 chemotherapy agents) during induction therapy in advanced stage HPV negative patients can significantly shrink the subject's cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have pathologically confirmed locally advanced, non-metastatic, HPV-negative head and neck squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, nasopharynx, larynx, or sinuses.
- •Stage IV disease with the exception of nasopharyngeal tumor-3, node-2 (stage III) based of American Joint Committee on Cancer staging 8th edition
- •If a primary oropharyngeal squamous cell carcinoma is diagnosed, HPV must be ruled out by immunohistochemistry.
- •Availability of ≥10 unstained 5 micron slides. Patients who cannot fulfill this requirement will need to undergo a new biopsy prior to enrollment on study.
- •Patients must be at least 18 years of age.
- •Measurable disease (either primary site and/or nodal disease) by RECIST criteria.
- •No previous radiation or chemotherapy for a head and neck cancer.
- •No complete surgical resection for a head and neck cancer within 8 weeks of enrollment (although lymph node biopsy including excision of an individual node with presence of residual nodal disease, or surgical biopsy/excision of the tumor with residual measurable disease is acceptable.) No surgical procedures or biopsies will occur after baseline scans are performed and measurable lesions are identified.
- •Eastern Cooperative Oncology Group performance status 0-1
- •Normal Organ Function
- •Leukocytes ≥ 3000/mm3
- •Platelets ≥ 100,000/mm3
- •Absolute neutrophil count ≥ 1,500
- •Hemoglobin ≥ 9.0 gm/dL
- •Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 2.5x upper limit of normal
- •Alkaline phosphatase ≤ 2.5x upper limit of normal
- •Albumin > 2.9 gm/dL
- •Total bilirubin ≤ 1.5 mg/dL
- •Creatinine clearance > 45 mL/min, normal within 2 weeks prior to start of treatment (Of note, the standard Cockcroft and Gault formula must be used to calculate creatinine clearance (CrCl) for enrollment or dosing)
- •Patients must sign a study-specific informed consent form prior to study entry. Patients should have the ability to understand and the willingness to sign a written informed consent document.
- •Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug
- •Women must not be breastfeeding
- •Women of childbearing potential must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) plus 6 months after completing chemoradiation or receiving the last dose of consolidative nivolumab, whichever occurs latest.
- •Men who are sexually active with women of childbearing potential must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) plus 6 months after completing chemoradiation or receiving the last dose of consolidative nivolumab, whichever occurs latest.
排除标准
- •Unequivocal demonstration of distant metastatic disease (M1 disease).
- •Unidentifiable primary site.
- •Inter-current medical illnesses which would impair patient tolerance to therapy or limit survival. This includes but is not limited to ongoing or active infection, immunodeficiency, symptomatic congestive heart failure, pulmonary dysfunction, cardiomyopathy, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance. Patients with clinically stable and/or chronically managed medical illnesses that are not symptomatic and/or are not expected to impact treatment on protocol are still eligible (conditions to be reviewed by the PI to confirm eligibility)
- •Prior surgical therapy other than incisional/excisional biopsy or organ-sparing procedures such as debulking of airway-compromising tumors. Residual measurable tumor is required for enrollment as discussed above.
- •Patients receiving other investigational agents.
- •Diagnosis of immunodeficiency or is receiving systemic steroid therapy in excess of physiologic dose or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
- •Known history of active tuberculosis (Bacillus Tuberculosis infection).
- •Hypersensitivity to nivolumab or any other drug used in this protocol.
- •Prior systemic anti-cancer treatment within the last 8 weeks.
- •Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer or any tumors that are not likely to influence life expectancy in the subsequent 3 years without active treatment.
- •Has active autoimmune disease that has required systemic therapy in the past year (i.e. with steroids or immunosuppressive drugs). Replacement therapy e.g. levothyroxine, insulin, or physiologic corticosteroid doses for adrenal or pituitary insufficiency, etc. are not considered a form of systemic treatment.
- •Has known history of, or any evidence of active, non-infectious pneumonitis.
- •Has a history of HIV.
- •Has known active Hepatitis B or hepatitis C. If eradicated, patient is eligible.
- •Has received a live vaccine within 28 days of planned start of study therapy.
研究组 & 干预措施
De-escalated Chemotherapy
Experimental
Radiation therapy with chemotherapy
干预措施: Hydroxyurea Pill (Drug)
Standard Chemotherapy
Experimental
Induction Therapy
干预措施: Carboplatin (Drug)
Standard Chemotherapy
Experimental
Induction Therapy
干预措施: Paclitaxel (Drug)
Standard Chemotherapy
Experimental
Induction Therapy
干预措施: Nivolumab (Drug)
De-escalated Chemotherapy
Experimental
Radiation therapy with chemotherapy
干预措施: Paclitaxel (Drug)
De-escalated Chemotherapy
Experimental
Radiation therapy with chemotherapy
干预措施: Radiation (Radiation)
De-escalated Chemotherapy
Experimental
Radiation therapy with chemotherapy
干预措施: 5-fluorouracil (Drug)
De-escalated Chemotherapy
Experimental
Radiation therapy with chemotherapy
干预措施: Filgrastim Injection (Drug)
De-escalated Chemotherapy
Experimental
Radiation therapy with chemotherapy
干预措施: Cisplatin (Drug)
结局指标
主要结局
Deep Response Rate (DRR)
时间窗: 2 years
DRR is 50% or greater response to induction therapy based on RECIST criteria. The objective is to intensify induction chemotherapy with the addition of an immune checkpoint inhibitor aimed at increasing the proportion of patients achieving a deep tumor response in order to subsequently allow risk-adapted definitive chemoradiotherapy in advanced stage HPV negative head and neck squamous cell cancer patients.
次要结局
- Locoregional Control After Completing Chemoradiation(26 months)
- Progression Free Survival Rate (PFS)(26 months)
- Overall Survival Rate (OS)(26 months)
- Distant Control After Completing Chemoradiation(26 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by SurgeryName Human Papillomavirus Positive Oropharyngeal Squamous Cell CarcinomaStage II Oropharyngeal Squamous Cell CarcinomaStage III Hypopharyngeal Squamous Cell CarcinomaStage III Laryngeal Squamous Cell CarcinomaStage III Oral Cavity Squamous Cell CarcinomaStage III Oropharyngeal Squamous Cell CarcinomaStage IV Hypopharyngeal Squamous Cell CarcinomaStage IV Laryngeal Squamous Cell CarcinomaStage IV Oral Cavity Squamous Cell CarcinomaStage IV Oropharyngeal Squamous Cell CarcinomaStage IVA Hypopharyngeal Squamous Cell CarcinomaStage IVA Laryngeal Squamous Cell CarcinomaStage IVA Oral Cavity Squamous Cell CarcinomaStage IVA Oropharyngeal Squamous Cell CarcinomaStage IVB Hypopharyngeal Squamous Cell CarcinomaStage IVB Laryngeal Squamous Cell CarcinomaStage IVB Oral Cavity Squamous Cell CarcinomaStage IVB Oropharyngeal Squamous Cell CarcinomaStage IVC Hypopharyngeal Squamous Cell CarcinomaStage IVC Laryngeal Squamous Cell CarcinomaStage IVC Oral Cavity Squamous Cell CarcinomaStage IVC Oropharyngeal Squamous Cell CarcinomaNCT03342911Sidney Kimmel Cancer Center at Thomas Jefferson University34
已完成
2 期
Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung CancerExtensive Stage Lung Small Cell CarcinomaRecurrent Lung Small Cell CarcinomaNCT03382561National Cancer Institute (NCI)160
已完成
2 期
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant MelanomaMelanoma (Skin)NCT00976573Alliance for Clinical Trials in Oncology149
终止
2 期
Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung CancerLarge Cell Lung CarcinomaLung AdenocarcinomaRecurrent Non-Small Cell Lung CarcinomaStage IV Non-Small Cell Lung CancerBronchioloalveolar Lung CarcinomaNCT00955305National Cancer Institute (NCI)175
已完成
2 期
Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By SurgeryRecurrent MelanomaStage IV MelanomaNCT00255762National Cancer Institute (NCI)47